BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.

Biotechnology

Clinical Trials

Therapeutics

BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology Therapeutics (BBOT)

Org chart

Teams

Similar companies